Valley Medical Pharmacy 
630 Main Street 
Brawley, CA 92227 
eRx ID#0585957 
1 (800) 322-0808 | Toll Free Fax: 1 (855) 322-0808 
Email: drugsdepot@yahoo.com 
Web: www.drugsdepot 
Timing: Monday to Friday | 9:00 AM to 5:45 PM 


Menu

Anagrelide Hcl Generic Agrylin 0.5 Mg Caps 100 By Teva Pharma

Image 0 of Anagrelide Hcl Generic Agrylin 0.5 Mg Caps 100 By Teva PharmaImage 1 of Anagrelide Hcl Generic Agrylin 0.5 Mg Caps 100 By Teva Pharma

Anagrelide Hcl Generic Agrylin 0.5 Mg Caps 100 By Teva Pharma

Call for Price

Anagrelide Hcl Generic Agrylin 0.5 Mg Caps 100 By Teva Pharma. This Item Requires A Valid Order From A Physician Licensed in USA. Item Number.:RXD3661360/RXB10053714/RXA317860
Size : 100
Selling UoM : EA
NDC: 00172-5241-60
UPC Barcode : 301725241601
Supplier: 0050001781 TEVA PHARMACEUTICALS USA
Supplier Material : 524160
Generic Code : 030949 ANAGRELIDE HCL ORAL CAPSULE 0.5 MG
Fine Line Class : 850085008510 All Rx Products
Product Category : RX Pharmaceuticals
Product

Have a question?

  Call for Price

Product Description.:

Logo and 5241, 0.5 mg
capsule , gray white , oblong oblong
Black ink

Name: AGRYLIN (anagrelide hydrochloride)

Dosage Form: 0.5 mg capsules for oral administration

Active Ingredient: AGRYLIN? Capsules contain 0.5 mg of anagrelide base (as anagrelide hydrochloride).

Inactive Ingredients: Anhydrous Lactose NF, Crospovidone NF, Lactose Monohydrate NF, Magnesium stearate NF, Microcrystalline cellulose NF, Povidone USP.

Pharmacological Classification: Platelet-reducing agent.

Chemical Name: 6,7-dichloro-1,5-dihydroimidazo[2,1-b]quinazolin-2(3H)-one monohydrochloride monohydrate.

Molecular formula: C10H7Cl2N3O?HCl?H2O

INDICATIONS

AGRYLIN? Capsules are indicated for the treatment of patients with thrombocythemia, secondary to myeloproliferative disorders, to reduce the elevated platelet count and the risk of thrombosis and to ameliorate associated symptoms including thrombo-hemorrhagic events.

WARNINGS
Cardiovascular

Anagrelide should be used with caution in patients with known or suspected heart disease, and only if the potential benefits of therapy outweigh the potential risks. Because of the positive inotropic effects and side-effects of anagrelide, a pre-treatment cardiovascular examination is recommended along with careful monitoring during treatment. In humans, therapeutic doses of anagrelide may cause cardiovascular effects, including vasodilation, tachycardia, palpitations, and congestive heart failure.
Hepatic

Exposure to anagrelide is increased 8-fold in patients with moderate hepatic impairment (see CLINICAL PHARMACOLOGY). Use of anagrelide in patients with severe hepatic impairment has not been studied. The potential risks and benefits of anagrelide therapy in a patient with mild and moderate impairment of hepatic function should be assessed before treatment is commenced. In patients with moderate hepatic impairment, dose reduction is required and patients should be carefully monitored for cardiovascular effects (see DOSAGE AND ADMINISTRATION for specific dosing recommendations).
Interstitial Lung Diseases

Interstitial lung diseases (including allergic alveolitis, eosinophilic pneumonia and interstitial pneumonitis) have been reported to be associated with the use of anagrelide in post-marketing reports. Most cases presented with progressive dyspnea with lung infiltrations. The time of onset may range from 1 week to several years after initiating anagrelide. In most cases, the symptoms improved after discontinuation of anagrelide